Drug efficacy was thus evaluated in short-term (3 days) or long-term (12 days) cultures of cancer cell lines, including a colorectal cancer cell line with (DLD1-KO) or without BRCA2 knockout (DLD1-P). This evidence concerns the gene BRCA2 and colorectal cancer.